Get the Stockscreener App
1.19
0.83%
-0.01
Eagle Pharmaceuticals Inc stock is traded at $1.19, with a volume of 1,063.
It is down -0.83% in the last 24 hours and down -76.15% over the past month.
See More
Previous Close:
$1.20
Open:
$1.2
24h Volume:
1,063
Relative Volume:
34.89
Market Cap:
$N/A
Revenue:
$257.55M
Net Income/Loss:
$11.95M
P/E Ratio:
1.3077
EPS:
0.91
Net Cash Flow:
$-9.39M
1W Performance:
+47.50%
1M Performance:
-76.15%
6M Performance:
-81.21%
1Y Performance:
-93.26%
1-Day Range:
$1.20
$1.20
1-Week Range:
$1.20
$1.20
52-Week Range:
$1.20
$1.20
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Compare EGRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
1.20 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
|
ZTS
Zoetis Inc
|
168.88 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.60 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.16 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.30 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-01-18 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Mar-21-18 | Reiterated | Mizuho | Underperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | RBC Capital Mkts | Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-09-17 | Downgrade | Mizuho | Neutral → Underperform |
| Nov-16-16 | Downgrade | Mizuho | Buy → Neutral |
| Nov-03-16 | Upgrade | Mizuho | Neutral → Buy |
| Nov-03-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-26-16 | Reiterated | Mizuho | Buy |
| Aug-16-16 | Reiterated | Mizuho | Neutral |
| Jun-20-16 | Downgrade | Mizuho | Buy → Neutral |
| May-10-16 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-18-16 | Reiterated | Mizuho | Buy |
| Feb-26-16 | Reiterated | Mizuho | Buy |
| Dec-09-15 | Initiated | Mizuho | Buy |
| Jul-29-15 | Reiterated | Piper Jaffray | Overweight |
View All
Eagle Pharmaceuticals Inc Stock (EGRX) Latest News
EGRX STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Eagle Pharmaceuticals, Inc. (EGRX) - ACCESS Newswire
Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX)February 9, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Eagle Pharmaceuticals, Inc. (EGRX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc. (EGRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. Enters Third Amended and Restated Credit Agreement - Marketscreener.com
Jane Street Group LLC Makes New Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09% - MSN
Antiemetics Drugs Market Size & Share Report, 2024 – 2032 - Global Market Insights
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Last Week's Biggest Stock Movers: Eagle, Noodles & Co. - AOL
Eagle Pharmaceuticals Enters Into Settlement Agreement With Dr. Reddy's Laboratories on Leukemia Drug - Marketscreener.com
Eagle Pharmaceuticals : to Present at Jefferies Virtual Healthcare Conference 2021 - Marketscreener.com
Eagle Pharmaceuticals Amends Rights Agreement with Equiniti Trust Company - Defense World
Eagle Pharmaceuticals amends rights agreement - Investing.com
Eagle Pharmaceuticals amends rights agreement By Investing.com - Investing.com Nigeria
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
Eagle Pharmaceuticals Dismisses Ernst & Young LLP as Independent Registered Public Accounting Firm - Defense World
Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal - Investing.com
Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceutica - GuruFocus.com
Eagle Pharma Founder Sues Company to Recoup Cost of SEC Investigation - Law.com
Ex-Pharma CEO Demands Legal Fees For SEC Probe - Law360
Eagle Pharmaceuticals names Christopher Krawtschuk as CFO - MSN
Eagle Pharmaceuticals to Delist from Nasdaq By Investing.com - Investing.com Australia
Eagle Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
Eagle Pharmaceuticals to Delist from Nasdaq - Investing.com India
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration - The Manila Times
Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension | EGRX Stock News - StockTitan
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Citigroup Inc's Strategic Reduction in Eagle Pharmaceuticals Inc Shares - GuruFocus.com
Creative Planning Makes New $59,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerWOODCLIFF LAKE, N.J. — November 12, 2024 — Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) recently announced the appointment of Christopher Krawtschuk as the Chief - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - The Manila Times
Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Some Major Key Players In The Heparin-Induced Thrombocytopenia (HIT) Treatment Market: - InsightAce Analytic
Nantahala Capital Management Reduces Stake in Eagle Pharmaceuticals - GuruFocus.com
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’S Disease in Collaboration with University of Pennsylvania - Marketscreener.com
Eagle Pharmaceuticals Adopts Stockholder Rights Plan to Protect Shareholders’ Interests - Defense World
Union Square Park Capital Management, LLC Increases Stake in Eagle Pharmaceuticals Inc - GuruFocus.com
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.99%
Cap:
|
Volume (24h):